Replies to post #411013 on Amarin Corp Plc (AMRN)

[RobinF]

Patients over 60 have no co-pay on the NHS - at least that is how it is right now.

[ziploc_1]

Capt....Your information makes me optimistic about the future of Vascepa in the U.K...

Omacor, a successful competitor to Vascepa, has been shown to be useless in reducing CVD....Nessen advised AstraZeneca to buy Omacor for millions of dollars and then spend many more millions for a study to prove its effectiveness in reducing CVD... only to see it fail...Somehow, this embittered Doc came to blame Vascepa for his mistakes and, ever since, he has been bad mouthing Vascepa, which was successful in doing what he had tried to do and failed...This unfortunate episode has caused a stain on the history of Dr. Nessen's career.